Sun Pharmaceutical Industries Ltd (Sun Pharma) is a global specialty generic pharmaceutical company. The company's primary activities include the manufacture and marketing of a broad spectrum of pharmaceutical formulations, including generics, branded generics, specialty, complex or difficult-to-make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates. Sun Pharma serves a wide range of chronic and acute therapies and invests heavily in research and development. Sun Pharma's business portfolio is diverse and comprehensive.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Sun Pharma's R&D arm focuses on developing innovative medicines, complex generics, and novel formulations. The company invests significantly in research and development to advance its pipeline, strengthen its generics portfolio, and build differentiated products that address unmet patient needs. The R&D efforts are supported by a global ecosystem integrating scientific expertise, clinical development capabilities, and technology-driven innovation. The company emphasizes technology absorption, adaptation, and innovation, with a focus on developing complex products, specialty products, generic formulations, and active pharmaceutical ingredient (API) technologies. The company also prioritizes environmental sustainability, process safety, and regulatory compliance through product design and process optimization. Sun Pharma's R&D units are responsible for a wide range of activities, including clinical trials, finished dosage development, biological support, chemistry, and new drug development. The units focus on developing differentiated products such as liposomal delivery systems, inhalers, lyophilized injections, nasal sprays, and controlled and modified release dosage forms. The R&D units also play a critical role in supporting the development of innovative medicines, complex and non-infringing formulations, and ensuring regulatory compliance. Sun Pharma operates 6 global R&D centers and has a strong R&D team comprising over 2,900 professionals. The company holds close to 2,400 patents and has developed and filed approximately 300 product dossiers globally. The R&D efforts are supported by major technology alliances and collaborations aimed at enhancing scientific capabilities and advancing the company's pipeline. The company has developed and filed 86 formulations for the Indian and regulated markets and submitted 152 dossiers in emerging markets. To support a diverse portfolio, the company focuses on strong R&D capabilities with an extensive commercial network, including tablets, capsules, injectables, sprays, ointments, creams, and liquids markets, effectively. In FY2026, the Company has also filed 53 drug master files across various markets. In FY2026, the company incurred an R&D expense of INR34,713.7 million, which as a percentage of the company's revenue stood at 5.9%. The company submitted 674 ANDAs, 70 NDAs/BLAs, and 3,303 patents for FY2026. From these filings, 552 ANDAs, 57 NDAs/BLAs, and 2,542 patents were granted.